UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
UCB, a global biopharmaceutical company, today announced that the Phase 3 study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and most key...